Quick Answer
MoonLake Immunotherapeutics reported Net Income of -$227.32 million for fiscal year 2025.
MoonLake Immunotherapeutics — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$227.32M -91.1% |
-$118.94M -230.3% |
-$36.01M +27.9% |
-$49.97M -1000.1% |
-$4.54M | — |
| Diluted EPS | -$3.53 -86.8% |
-$1.89 -158.9% |
-$0.73 +57.1% |
-$1.70 | — | — |
| Total Assets | $424.43M -11.2% |
$477.93M -9.2% |
$526.54M +585.2% |
$76.84M +693.6% |
$9.68M -91.7% |
$116.63M |
| Cash and Equivalents | $334.52M +85.4% |
$180.43M -60.0% |
$451.17M +1042.0% |
$39.51M +391.4% |
$8.04M +501.7% |
$1.34M |
| Long-Term Debt | $74.10M | $0.00 | — | — | — | — |
| Stockholders Equity | $304.48M -31.9% |
$446.82M -9.9% |
$495.68M +913.7% |
$48.90M +45810.9% |
$106.5K +104.2% |
-$2.52M |
| R&D Expense | $202.86M +79.9% |
$112.77M +254.6% |
$31.80M -24.4% |
$42.05M | — | — |
| Operating Income | -$244.83M -71.1% |
-$143.09M -164.4% |
-$54.12M +16.8% |
-$65.06M -1323.6% |
-$4.57M | — |
| Shares Outstanding | — | — | — | 52.70M | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$69.73M | -97.0% | -26.3% |
| Diluted EPS | September 30, 2025 | -$1.10 | -96.4% | -26.4% |
| Total Assets | September 30, 2025 | $414.33M | -20.0% | -9.9% |
| Cash and Equivalents | September 30, 2025 | $350.74M | -6.6% | +14.4% |
| Long-Term Debt | September 30, 2025 | $73.74M | — | +0.5% |
| Stockholders Equity | September 30, 2025 | $288.91M | -40.8% | -18.3% |
| R&D Expense | September 30, 2025 | $60.63M | +69.7% | +21.9% |
| Operating Income | September 30, 2025 | -$71.43M | -65.7% | -17.7% |
| Shares Outstanding | March 31, 2022 | 52.70M | — | — |
- MoonLake Immunotherapeutics reported Net Income of -$227.32 million for fiscal year 2025.
- MoonLake Immunotherapeutics showed a decrease of -91.1% in Net Income compared to the prior fiscal year.
- MoonLake Immunotherapeutics reported Diluted EPS of $3.53 per share (loss) for fiscal year 2025.
- MoonLake Immunotherapeutics showed a decrease of -86.8% in Diluted EPS compared to the prior fiscal year.
- MoonLake Immunotherapeutics reported Total Assets of $424.43 million for fiscal year 2025.
- MoonLake Immunotherapeutics showed a decrease of -11.2% in Total Assets compared to the prior fiscal year.
- MoonLake Immunotherapeutics reported Cash and Equivalents of $334.52 million for fiscal year 2025.
- MoonLake Immunotherapeutics showed an increase of +85.4% in Cash and Equivalents compared to the prior fiscal year.
- MoonLake Immunotherapeutics reported Long-Term Debt of $74.10 million for fiscal year 2025.
- MoonLake Immunotherapeutics reported Stockholders Equity of $304.48 million for fiscal year 2025.
- MoonLake Immunotherapeutics showed a decrease of -31.9% in Stockholders Equity compared to the prior fiscal year.
- MoonLake Immunotherapeutics reported R&D Expense of $202.86 million for fiscal year 2025.
- MoonLake Immunotherapeutics showed an increase of +79.9% in R&D Expense compared to the prior fiscal year.
- MoonLake Immunotherapeutics reported Operating Income of -$244.83 million for fiscal year 2025.
- MoonLake Immunotherapeutics showed a decrease of -71.1% in Operating Income compared to the prior fiscal year.
- MoonLake Immunotherapeutics reported Shares Outstanding of 52.70 million shares for fiscal year 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: